首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2103018

免疫診斷市場－策略分析與預測（2026-2035）

Immunodiagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計免疫診斷市場將從 2026 年的 359 億美元成長到 2035 年的 575 億美元，複合年成長率為 5.4%。

全球免疫診斷市場正經歷強勁成長，這主要得益於醫療保健系統擴大採用先進的體外診斷技術，用於感染疾病、慢性病、自體免疫疾病和癌症的早期檢測、診斷和後續觀察。免疫診斷利用抗原-抗體交互作用來識別與各種疾病相關的生物標記物，是醫院、診斷檢查室、血庫、研究機構和即時檢測（POC）機構中最廣泛使用的診斷方法之一。疾病盛行率的上升、醫療保健基礎設施的不斷完善、預防醫學意識的增強以及對精準臨床檢測需求的日益成長，都持續推動著市場擴張。

該市場涵蓋免疫檢測設備、試劑、耗材、快速診斷試劑盒、校準樣品、品管樣品和檢查室軟體。持續的技術進步顯著提高了檢測的靈敏度、特異性、自動化程度、多參數檢測能力以及結果報告速度。現代免疫診斷平台將化學冷光、螢光、酵素免疫分析法(ELISA)、免疫檢測和先進免疫檢測技術與實驗室資訊系統結合，使檢查室能夠提供更快、更可靠的診斷結果。

對疾病早期檢測日益成長的需求推動了免疫診斷檢測在腫瘤學、循環系統、內分泌學、感染疾病管理、過敏檢測和自體免疫疾病診斷等領域的應用擴展。對個人化醫療、精準診斷和伴隨診斷的日益重視也為免疫診斷技術創造了新的機會。製藥和生物技術公司正擴大利用免疫診斷平台進行藥物研發、臨床試驗、生物標記鑑定和治療監測。

全球醫療機構正加大對檢查室自動化和數位轉型的投資，以提高營運效率和診斷準確性。即時檢測的普及、醫療支出的成長、政府的支持措施以及新興經濟檢查室現代化計畫的進展，預計將在預測期內推動市場持續成長。隨著診斷技術的不斷發展，免疫診斷仍將是現代臨床實驗室醫學的基石。

市場促進因素

感染疾病和慢性病盛行率不斷上升

感染疾病、癌症、心血管疾病、自體免疫疾病和代謝性疾病發生率的不斷上升，顯著推動了對免疫學診斷檢測的需求。早期準確的診斷能夠達到及時的臨床干預，進而改善患者的預後。

對疾病早期檢測的需求日益成長

醫療機構越來越重視預防醫學和定期篩檢計畫。免疫診斷技術能夠快速、高靈敏度和高特異性地檢測疾病生物標記物，從而支持早期診斷和治療方案的發展。

檢查室自動化擴展

在臨床檢查室中，自動化免疫檢測系統正被日益廣泛地引入，以簡化工作流程、減少人為誤差、提高檢測能力並縮短結果報告時間。自動化是推動高檢測量診斷檢查室採用這些系統的關鍵因素。

免疫檢測技術的進步

化學冷光免疫檢測、螢光免疫分析測定、多參數檢測、數位診斷、人工智慧和實驗室資訊管理系統的不斷創新，正在提高分析性能並擴大臨床應用範圍。

加大對醫療基礎建設的投資

各國政府和私人醫療機構，尤其是在新興經濟體，正持續擴大診斷基礎設施。這些投資提高了先進免疫診斷技術的普及率，並支持了市場的長期成長。

市場限制因素

先進診斷系統高成本

全自動免疫診斷分析儀需要大量的資金投入，這使得資金有限的小規模檢查室和醫療機構難以實施。

嚴格的監管要求

在商業化之前，製造商必須遵守全面的監管標準，這些標準規範分析性能、產品品質、臨床檢驗和生產規範。

與保險報銷相關的問題

由於各國的報銷政策不同，先進免疫診斷測試的引入可能會受到限制，尤其是在專門的生物標記分析方面。

與分子診斷的競爭

分子診斷、基因檢測和次世代定序技術的快速發展，正在多個疾病領域補充傳統的免疫診斷方法。

對熟練人員的需求

操作先進的免疫診斷平台需要訓練有素的實驗室專業人員，他們能夠維護設備、確保品質並準確解讀複雜的診斷結果。

依產品
- 試劑和試劑盒
- 裝置
- 軟體和服務
透過技術
- 酵素免疫分析法（ELISA）
- 化學冷光免疫檢測（CLIA）
- 螢光免疫分析（FIA）
- 免疫測量（RIA）
- 多重免疫檢測
- 其他免疫檢測技術
依樣本類型
- 血液/血清
- 電漿
- 尿
- 唾液
- 腦脊髓液（CSF）
- 其他類型的樣本
透過使用
- 感染疾病
- 瘤
- 循環系統
- 自體免疫疾病
- 內分泌學
- 藥物監測
- 其他臨床用途
最終用戶
- 醫院和診所
- 臨床實驗室
- 學術研究機構
- 其他最終用戶

第10章：全球免疫診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球免疫診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、合作與聯盟
新產品發布

第13章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Danaher Corporation
Thermo Fisher Scientific Inc.
Merck KGaA
Bio-Rad Laboratories, Inc.
QuidelOrtho Corporation
Sysmex Corporation
Becton, Dickinson and Company（BD）
DiaSorin SpA
Fujirebio Holdings, Inc.
Revvity, Inc.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Trinity Biotech plc

第14章全球免疫診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009022

The Immunodiagnostics Market is expected to grow at a CAGR of 5.4% from a market value of USD 35.9 billion in 2026 to USD 57.5 billion in 2035.

The global immunodiagnostics market is experiencing robust growth as healthcare systems increasingly adopt advanced in vitro diagnostic technologies for the early detection, diagnosis, and monitoring of infectious diseases, chronic disorders, autoimmune diseases, and cancer. Immunodiagnostics utilizes antigen-antibody interactions to identify biomarkers associated with various diseases, making it one of the most widely used diagnostic approaches across hospitals, diagnostic laboratories, blood banks, research institutes, and point-of-care settings. Rising disease prevalence, expanding healthcare infrastructure, growing awareness of preventive healthcare, and increasing demand for accurate laboratory diagnostics continue to drive market expansion.

The market comprises immunoassay analyzers, reagents, consumables, rapid diagnostic kits, calibration materials, quality controls, and laboratory software. Continuous technological advancements have significantly improved assay sensitivity, specificity, automation, multiplex testing capabilities, and turnaround times. Modern immunodiagnostic platforms integrate chemiluminescence, fluorescence, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, and advanced immunoassay technologies with laboratory information systems, enabling laboratories to deliver faster and more reliable diagnostic results.

Increasing demand for early disease detection has strengthened the adoption of immunodiagnostic testing in oncology, cardiology, endocrinology, infectious disease management, allergy testing, and autoimmune disease diagnosis. The growing emphasis on personalized medicine, precision diagnostics, and companion diagnostics is also creating new opportunities for immunodiagnostic technologies. Pharmaceutical and biotechnology companies increasingly utilize immunodiagnostic platforms during drug discovery, clinical trials, biomarker identification, and therapeutic monitoring.

Healthcare providers worldwide are investing in laboratory automation and digital transformation to improve operational efficiency and diagnostic accuracy. Expanding point-of-care testing, increasing healthcare expenditure, favorable government initiatives, and growing laboratory modernization programs in emerging economies are expected to support sustained market growth during the forecast period. As diagnostic technologies continue to evolve, immunodiagnostics will remain a cornerstone of modern clinical laboratory medicine.

Market Drivers

Rising Prevalence of Infectious and Chronic Diseases

The increasing incidence of infectious diseases, cancer, cardiovascular disorders, autoimmune diseases, and metabolic conditions is significantly driving demand for immunodiagnostic testing. Early and accurate diagnosis enables timely clinical intervention and improves patient outcomes.

Growing Demand for Early Disease Detection

Healthcare providers are increasingly emphasizing preventive healthcare and routine screening programs. Immunodiagnostic technologies provide rapid, sensitive, and highly specific detection of disease biomarkers, supporting early diagnosis and treatment planning.

Expansion of Laboratory Automation

Clinical laboratories are adopting automated immunoassay systems to improve workflow efficiency, reduce manual errors, increase testing capacity, and shorten turnaround times. Automation has become a key factor driving adoption across high-volume diagnostic laboratories.

Technological Advancements in Immunoassays

Continuous innovation in chemiluminescence immunoassays, fluorescence immunoassays, multiplex testing, digital diagnostics, artificial intelligence, and laboratory information management systems is improving analytical performance and expanding clinical applications.

Increasing Investments in Healthcare Infrastructure

Governments and private healthcare organizations continue to expand diagnostic infrastructure, particularly across emerging economies. These investments are increasing access to advanced immunodiagnostic technologies while supporting long-term market growth.

Market Restraints

High Cost of Advanced Diagnostic Systems

Fully automated immunodiagnostic analyzers require substantial capital investment, making adoption difficult for smaller laboratories and healthcare facilities with limited financial resources.

Stringent Regulatory Requirements

Manufacturers must comply with comprehensive regulatory standards governing analytical performance, product quality, clinical validation, and manufacturing practices before commercialization.

Reimbursement Challenges

Variations in reimbursement policies across countries may limit adoption of advanced immunodiagnostic tests, particularly for specialized biomarker analysis.

Competition from Molecular Diagnostics

Rapid advances in molecular diagnostics, genetic testing, and next-generation sequencing technologies are complementing traditional immunodiagnostic methods in several disease areas.

Skilled Workforce Requirements

Operation of sophisticated immunodiagnostic platforms requires trained laboratory professionals capable of instrument maintenance, quality assurance, and accurate interpretation of complex diagnostic results.

Technology and Segment Insights

The immunodiagnostics market can be segmented by product, technology, application, end user, and geography.

By Product

Reagents and consumables account for the largest market share because every immunodiagnostic test requires specialized antibodies, antigens, buffers, substrates, calibrators, and quality control materials. Continuous laboratory testing generates recurring demand for these products.

Immunodiagnostic analyzers continue to experience strong growth as healthcare facilities increasingly invest in automated laboratory systems capable of handling high testing volumes with improved analytical accuracy.

Software solutions, quality control products, and laboratory information management systems are becoming increasingly important as laboratories pursue digital transformation and workflow optimization.

By Technology

Chemiluminescence immunoassays represent a major technology segment owing to their high sensitivity, automation compatibility, and widespread use in clinical laboratories.

Enzyme-linked immunosorbent assay (ELISA) remains extensively utilized across clinical diagnostics, biomedical research, and pharmaceutical applications because of its reliability and cost-effectiveness.

Fluorescence immunoassays, radioimmunoassays, rapid immunochromatographic tests, and multiplex immunoassays continue to expand their presence across diverse diagnostic applications.

By Application

Infectious disease diagnosis remains the largest application segment due to increasing global demand for rapid detection of viral, bacterial, and parasitic infections.

Oncology diagnostics continues to grow rapidly as immunodiagnostic biomarkers support cancer screening, diagnosis, prognosis, and therapeutic monitoring.

Autoimmune disease testing, endocrinology, cardiology, allergy diagnostics, therapeutic drug monitoring, and toxicology also contribute substantially to market demand.

By End User

Hospitals represent the largest end-user segment because of high patient volumes and comprehensive diagnostic capabilities.

Independent diagnostic laboratories continue to strengthen market demand through centralized laboratory testing and specialized diagnostic services.

Academic research institutes, pharmaceutical companies, biotechnology organizations, and blood banks extensively utilize immunodiagnostic technologies for research, clinical trials, biomarker discovery, and blood screening.

By Geography

North America maintains the largest market share due to advanced healthcare infrastructure, extensive laboratory automation, significant research investments, and strong adoption of innovative diagnostic technologies.

Europe continues to experience steady growth supported by established healthcare systems, increasing investments in precision diagnostics, and strong regulatory standards.

Asia Pacific is projected to register the fastest growth owing to expanding healthcare infrastructure, rising healthcare expenditure, increasing disease burden, and growing adoption of advanced diagnostic technologies.

Latin America and the Middle East & Africa are gradually expanding their diagnostic capabilities through healthcare modernization initiatives and increased laboratory investments.

Competitive and Strategic Outlook

The competitive landscape includes diagnostic equipment manufacturers, biotechnology companies, life science organizations, laboratory automation providers, reagent manufacturers, and healthcare technology companies. Competition is centered on technological innovation, assay sensitivity, laboratory automation, digital connectivity, artificial intelligence integration, and comprehensive product portfolios.

Manufacturers continue to invest in next-generation immunodiagnostic platforms capable of delivering faster turnaround times, higher analytical accuracy, multiplex testing, and seamless integration with laboratory information systems. Strategic collaborations, acquisitions, research partnerships, regulatory approvals, and geographic expansion remain common growth strategies as companies strengthen their global market presence.

Growing demand for precision medicine, personalized healthcare, companion diagnostics, and decentralized testing is expected to create new growth opportunities throughout the forecast period. Companies capable of combining advanced immunoassay technologies with digital healthcare solutions are expected to maintain strong competitive positions.

Conclusion

The global immunodiagnostics market is expected to witness sustained growth throughout the forecast period, driven by rising prevalence of infectious and chronic diseases, increasing demand for early diagnosis, expanding laboratory automation, and continuous technological innovation. Advances in chemiluminescence immunoassays, ELISA, multiplex diagnostics, artificial intelligence, and digital laboratory management are improving diagnostic performance while enhancing healthcare efficiency. Although high equipment costs, regulatory complexities, reimbursement challenges, and competition from molecular diagnostics remain important market considerations, ongoing investments in healthcare infrastructure and diagnostic innovation are expected to support long-term expansion. The immunodiagnostics market will continue to serve as a critical component of modern clinical diagnostics by enabling accurate disease detection, therapeutic monitoring, and improved patient care.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Immunodiagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Overview of Immunodiagnostics
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Disease Burden and Diagnostic Demand Analysis
3.8 Testing Volume Analysis
3.9 Installed Base Analysis
3.10 Diagnostic Workflow and Patient Journey Analysis
3.11 Clinical Applications of Immunodiagnostics

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Immunodiagnostic Technologies
6.2 Product Innovation Analysis
6.3 Pipeline Analysis
6.4 Technology Roadmap
6.5 AI Integration in Immunodiagnostics
6.6 Digital Health Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Immunodiagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Product Type
8.3 Analysis by Sample Type
8.4 Analysis by Application
8.5 Analysis by Testing Methodology
8.6 Analysis by Automation Level

9. Global Immunodiagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Reagents & Kits
- 9.1.2 Instruments
- 9.1.3 Software & Services
9.2 By Technology
- 9.2.1 Enzyme-Linked Immunosorbent Assay (ELISA)
- 9.2.2 Chemiluminescence Immunoassay (CLIA)
- 9.2.3 Fluorescence Immunoassay (FIA)
- 9.2.4 Radioimmunoassay (RIA)
- 9.2.5 Multiplex Immunoassays
- 9.2.6 Other Immunoassay Technologies
9.3 By Sample Type
- 9.3.1 Blood & Serum
- 9.3.2 Plasma
- 9.3.3 Urine
- 9.3.4 Saliva
- 9.3.5 Cerebrospinal Fluid (CSF)
- 9.3.6 Other Sample Types
9.4 By Application
- 9.4.1 Infectious Diseases
- 9.4.2 Oncology
- 9.4.3 Cardiology
- 9.4.4 Autoimmune Diseases
- 9.4.5 Endocrinology
- 9.4.6 Therapeutic Drug Monitoring
- 9.4.8 Other Clinical Applications
9.5 By End User
- 9.5.1 Hospitals & Clinics
- 9.5.2 Clinical Diagnostic Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Other End Users

10. Global Immunodiagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Immunodiagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Abbott Laboratories
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 F. Hoffmann-La Roche Ltd.
13.3 Siemens Healthineers AG
13.4 Danaher Corporation
13.5 Thermo Fisher Scientific Inc.
13.6 Merck KGaA
13.7 Bio-Rad Laboratories, Inc.
13.8 QuidelOrtho Corporation
13.9 Sysmex Corporation
13.10 Becton, Dickinson and Company (BD)
13.11 DiaSorin S.p.A.
13.12 Fujirebio Holdings, Inc.
13.13 Revvity, Inc.
13.14 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
13.15 Trinity Biotech plc